June 24, 2020 / 1:24 PM / 18 days ago

BRIEF-Redhill Says COVID-19 Patients In Opaganib-Treated Group Discharged Without Needing Mechanical Ventilation

June 24 (Reuters) - Redhill Biopharma Ltd:

* PUBLICATION OF DATA FROM SEVERE COVID-19 PATIENTS SHOWS SUBSTANTIAL BENEFIT TO PATIENTS TREATED WITH REDHILL’S OPAGANIB COMPARED TO MATCHED CASE-CONTROL GROUP

* REDHILL BIOPHARMA LTD - ALL COVID-19 PATIENTS IN OPAGANIB-TREATED GROUP WERE DISCHARGED FROM HOSPITAL WITHOUT REQUIRING MECHANICAL VENTILATION

* REDHILL BIOPHARMA LTD - IN TRIAL, 33% OF MATCHED CASE-CONTROL GROUP REQUIRED MECHANICAL VENTILATION

* REDHILL - MEDIAN TIME TO WEANING FROM HIGH-FLOW NASAL CANNULA REDUCED TO 10 DAYS IN OPAGANIB-TREATED GROUP VERSUS 15 DAYS IN MATCHED CASE-CONTROL GROUP Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below